Pfizer to acquire Arena Pharmaceuticals

By The Science Advisory Board staff writers

December 14, 2021 -- Pfizer will acquire all outstanding shares of Arena Pharmaceuticals for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.

Arena's portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases, including gastrointestinal and dermatological diseases.

Arena has built a robust development program for etrasimod, including two phase III studies in ulcerative colitis (UC), a phase II/III program in Crohn's disease, a planned phase III program in atopic dermatitis, and ongoing phase II studies in eosinophilic esophagitis and alopecia areata. The data for the phase II OASIS trial for UC are expected to be reported in 2022.

Pfizer's financial advisors for the acquisition were Bank of America Securities and Centerview Partners while Ropes and Gray and Arnold and Porter Kaye Scholer acted as legal advisors. Guggenheim Securities and Evercore Group served as Arena's financial advisors, and Cooley served as its legal advisor.

Ranok Therapeutics, Pfizer team up on targeted protein degradation
Ranok Therapeutics and Pfizer are teaming up to evaluate Ranok's chaperone-mediated protein degradation platform technology on an undisclosed cancer target.
Pfizer partners with Voyager on AAV capsids
Pfizer has signed a deal to exercise its options to license novel capsids generated from Voyager Therapeutics' RNA-driven Tracer (tropism redirection...
Pfizer plans to acquire Trillium Therapeutics for $2.26B
Pfizer plans to acquire immuno-oncology drug developer Trillium Therapeutics for $2.26 billion in a deal that will expand Pfizer's portfolio to include...
Arena launches Longboard Pharmaceuticals
Arena Pharmaceuticals has launched Longboard Pharmaceuticals with $56 million in financing to support the development of the company's lead clinical...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter